Abivax SA
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod that is in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis, as … Read more
Abivax SA - Asset Resilience Ratio
Abivax SA (ABVX) has an Asset Resilience Ratio of 46.27% as of March 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2013–2024)
This chart shows how Abivax SA's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Abivax SA's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €69.71 Million | 41.76% |
| Short-term Investments | €7.53 Million | 4.51% |
| Total Liquid Assets | €77.24 Million | 46.27% |
Asset Resilience Insights
- Very High Liquidity: Abivax SA maintains exceptional liquid asset reserves at 46.27% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Abivax SA Industry Peers by Asset Resilience Ratio
Compare Abivax SA's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
MedPacto Inc
KQ:235980 |
Biotechnology | 49.82% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
|
Hualan Biological EngineeringInc
SHE:002007 |
Biotechnology | 14.68% |
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for Abivax SA (2013–2024)
The table below shows the annual Asset Resilience Ratio data for Abivax SA.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 42.59% | €87.40 Million | €205.23 Million | +34.28pp |
| 2023-12-31 | 8.30% | €27.16 Million | €327.06 Million | +8.29pp |
| 2022-12-31 | 0.02% | €12.00K | €73.35 Million | +0.01pp |
| 2021-12-31 | 0.01% | €12.00K | €110.36 Million | -0.01pp |
| 2020-12-31 | 0.02% | €12.00K | €71.30 Million | -0.01pp |
| 2019-12-31 | 0.02% | €12.00K | €51.73 Million | -18.50pp |
| 2018-12-31 | 18.52% | €10.01 Million | €54.05 Million | -37.78pp |
| 2017-12-31 | 56.31% | €30.30 Million | €53.81 Million | +6.64pp |
| 2016-12-31 | 49.67% | €30.10 Million | €60.60 Million | -1.47pp |
| 2015-12-31 | 51.15% | €39.01 Million | €76.27 Million | +46.66pp |
| 2014-12-31 | 4.49% | €1.70 Million | €37.97 Million | +3.45pp |
| 2013-12-31 | 1.04% | €400.00K | €38.46 Million | -- |